In SUM149 triple-negative breast cancer cells, expression of an activated form of STAT3 or an activated form of AKT strongly inhibited the lethality of (ruxolitinib + lapatinib) treatment (Figure 6A). The gene discussed is AKT1; the disease is triple-negative breast carcinoma.